[go: up one dir, main page]

AR127273A1 - BISPECIFIC ANTIBODIES THAT BIND SPECIFICALLY TO CD47 AND HER2 AND USES THEREOF - Google Patents

BISPECIFIC ANTIBODIES THAT BIND SPECIFICALLY TO CD47 AND HER2 AND USES THEREOF

Info

Publication number
AR127273A1
AR127273A1 ARP220102710A ARP220102710A AR127273A1 AR 127273 A1 AR127273 A1 AR 127273A1 AR P220102710 A ARP220102710 A AR P220102710A AR P220102710 A ARP220102710 A AR P220102710A AR 127273 A1 AR127273 A1 AR 127273A1
Authority
AR
Argentina
Prior art keywords
seq
amino acid
acid sequence
set forth
her2
Prior art date
Application number
ARP220102710A
Other languages
Spanish (es)
Inventor
Yizhen Yang
Yu Cai
Weigang He
Tianshu Xu
Xiong Li
Wei-Guo Su
Original Assignee
Hutchmed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchmed Ltd filed Critical Hutchmed Ltd
Publication of AR127273A1 publication Critical patent/AR127273A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención se relaciona con novedosos anticuerpos biespecíficos, que comprenden al menos un dominio de unión capaz de unirse específicamente a CD47 y al menos un dominio de unión capaz de unirse específicamente a HER2. La invención se relaciona además con métodos de producción de estos anticuerpos biespecíficos y a método de uso de los mismos. Reivindicación 1: Un anticuerpo biespecífico comprende (a) al menos un dominio de unión a antígeno capaz de unirse específicamente a CD47, y (b) al menos un dominio de unión a antígeno capaz de unirse específicamente a HER2, en donde el dominio de unión a antígeno capaz de unirse específicamente a CD47 comprende un VH y un VL, en donde el VH del dominio de unión al antígeno capaz de unirse específicamente a CD47 comprende HCDR1 que comprende o consiste en la secuencia de aminoácidos como se establece en SEQ ID Nº 11, HCDR2 que comprende o consiste en la secuencia de aminoácidos como se establece en SEQ ID Nº 12, y HCDR3 que comprende o consiste en la secuencia de aminoácidos como se establece en SEQ ID Nº 13 o 17 o 21, y el VL del dominio de unión a antígeno capaz de unirse específicamente a CD47 comprende LCDR1 que comprende o consiste en la secuencia de aminoácidos como se establece en SEQ ID Nº 14, LCDR2 que comprende o consiste en la secuencia de aminoácidos como se establece en SEQ ID Nº 15 o 18 o 22, y LCDR3 que comprende o consiste en la secuencia de aminoácidos como se establece en SEQ ID Nº 16.The invention relates to novel bispecific antibodies, which comprise at least one binding domain capable of specifically binding to CD47 and at least one binding domain capable of specifically binding to HER2. The invention also relates to methods of producing these bispecific antibodies and a method of using them. Claim 1: A bispecific antibody comprises (a) at least one antigen binding domain capable of specifically binding to CD47, and (b) at least one antigen binding domain capable of specifically binding to HER2, wherein the binding domain The antigen capable of specifically binding to CD47 comprises a VH and a VL, wherein the VH of the antigen binding domain capable of specifically binding to CD47 comprises HCDR1 comprising or consisting of the amino acid sequence as set forth in SEQ ID NO: 11 , HCDR2 comprising or consisting of the amino acid sequence as set forth in SEQ ID NO: 12, and HCDR3 comprising or consisting of the amino acid sequence as set forth in SEQ ID NO: 13 or 17 or 21, and the VL of the domain of antigen binding capable of specifically binding to CD47 comprises LCDR1 comprising or consisting of the amino acid sequence as set forth in SEQ ID NO: 14, LCDR2 comprising or consisting of the amino acid sequence as set forth in SEQ ID NO: 15 or 18 or 22, and LCDR3 comprising or consisting of the amino acid sequence as set forth in SEQ ID NO: 16.

ARP220102710A 2021-10-09 2022-10-06 BISPECIFIC ANTIBODIES THAT BIND SPECIFICALLY TO CD47 AND HER2 AND USES THEREOF AR127273A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2021122856 2021-10-09

Publications (1)

Publication Number Publication Date
AR127273A1 true AR127273A1 (en) 2024-01-03

Family

ID=85803940

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220102710A AR127273A1 (en) 2021-10-09 2022-10-06 BISPECIFIC ANTIBODIES THAT BIND SPECIFICALLY TO CD47 AND HER2 AND USES THEREOF

Country Status (3)

Country Link
AR (1) AR127273A1 (en)
TW (1) TW202330627A (en)
WO (1) WO2023056970A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR121805A1 (en) * 2020-04-10 2022-07-13 Hutchison Medipharma Ltd ANTI-CD47 ANTIBODY AND USES OF THE SAME

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122004000008I1 (en) * 1991-06-14 2005-06-09 Genentech Inc Humanized heregulin antibody.
MX2015012059A (en) * 2013-03-15 2016-01-12 Merck Patent Gmbh Tetravalent bispecific antibodies.
WO2018060301A1 (en) * 2016-09-30 2018-04-05 F. Hoffmann-La Roche Ag Bispecific antibodies against cd3
CN112745392B (en) * 2019-10-30 2022-07-01 上海洛启生物医药技术有限公司 anti-PD-L1/CD 47 bispecific antibody and application thereof
AR121805A1 (en) * 2020-04-10 2022-07-13 Hutchison Medipharma Ltd ANTI-CD47 ANTIBODY AND USES OF THE SAME

Also Published As

Publication number Publication date
WO2023056970A1 (en) 2023-04-13
TW202330627A (en) 2023-08-01

Similar Documents

Publication Publication Date Title
AR100573A1 (en) ANTIBODIES ANTI-IL-17, A METHOD FOR PRODUCING AND USING THEM
PE20210132A1 (en) ANTI-CD3 ANTIBODIES AND USES OF THEM
PE20200294A1 (en) ANTIBODIES THAT SPECIFICALLY BIND PD-1 AND METHODS OF USE
AR110017A1 (en) PD-1 ANTIBODIES AND USES OF THESE
PE20181921A1 (en) NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
AR106184A1 (en) PD-1 BINDING PROTEINS AND THEIR METHODS OF USE
AR112768A1 (en) ANTI-TIGIT ANTIBODIES
AR104906A1 (en) ANTIBODIES DIRECTED TO THE BONE MORPHOGENETIC PROTEIN 9 (BMP9) AND METHODS FROM THESE
AR073232A1 (en) ANTI-IL-17A / F BISPECIFIC ANTIBODIES AND WITH CROSSED REACTIVITY
AR095980A1 (en) SPECIFIC BIESPECTIFIC ANTIBODIES FOR FAP (FIBROBLASTIC ACTIVATION PROTEIN) AND DR5 (DEATH RECEIVER 5), SPECIFIC ANTIBODIES FOR DR5 AND METHODS OF USE
CO6331370A2 (en) ANTIBODIES AGAINST THE RECEIVER OF ADVANCED GLICOSILATION FINAL PRODUCTS (RAGE) AND USES OF THE SAME
CO6230999A2 (en) ANTI-SCLEROSTINE ANTIBODY
PE20240218A1 (en) AFFINITY MATURED AND HUMANIZED ANTIBODIES TO FCRH5
CL2010001544A1 (en) Humanized monoclonal antibody or binding fragment that binds and neutralizes the human vascular endothelial growth factor (hvegf); composition that includes it; nucleic acid coding; vector; host cell; its use to treat or prevent a disease mediated by vegf; and hybridoma.
AR123480A1 (en) THERAPEUTIC BINDING MOLECULES
AR065420A1 (en) ANTI-IL-23 P19 ENGINEERING ANTIBODIES
AR102417A1 (en) ANTI-TNF- / ANTI-IL-23 BIESPECTIFIC ANTIBODIES
PE20090161A1 (en) MONOCLONAL ANTIBODIES ANTI CXCL13
PE20142170A1 (en) ANTIBODIES AGAINST BRADYCININ B1 RECEPTOR LIGANDS
AR114281A1 (en) ANTI-KLK5 ANTIBODIES AND METHODS OF USE
CO2018001256A2 (en) Anti-cd154 antibodies and methods to produce them
PE20230389A1 (en) PROTEINS THAT COMPRISE BINDING DOMAINS TO THE CD3 ANTIGEN AND USES OF THESE
AR125212A1 (en) PROTEINS INCLUDING CD3 ANTIGEN-BINDING DOMAINS AND THEIR USES
AR110967A1 (en) MIMETIC ANTIBODIES FGF21 AND ITS USE
PE20221337A1 (en) TREM2 ANTIBODIES AND THEIR USES

Legal Events

Date Code Title Description
FB Suspension of granting procedure